SS31 10mg

Mitochondrial support peptide designed for cellular energy optimization. SS31 is a targeted bioactive compound that crosses the blood-brain barrier to support mitochondrial function and ATP production. Each vial contains 10mg of pharmaceutical-grade peptide, ideal for research and performance-focused protocols. Store at 2–8°C. For research purposes only.

Active Ingredient: SS31 (Elamipretide) Quantity: 10mg per vial Purity: Pharmaceutical grade Form: Lyophilized powder Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture Solubility: Reconstitute with sterile water or saline Molecular Weight: 623.7 Da Sequence: D-Arg-2’,6’-dimethyltyrosine-Lys-Phe-NH2 Application: Research and investigational use Sterility: Tested and certified Endotoxin: <5 EU/vial

Molecular Formula: C₃₄H₅₂N₁₀O₈ CAS Number: 736992-21-1 IUPAC Name: (2R)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid Exact Mass: 720.39 g/mol Chemical Class: Tetrapeptide analogue Structural Type: Mitochondrial-targeting peptide Composition: 4 amino acid residues with D-arginine modification Purity Grade: ≥98% (HPLC)

Storage Before Reconstitution: Temperature: 2–8°C (refrigerated) Container: Original sealed vial Light Protection: Store in dark conditions or original packaging Humidity: Keep in dry environment Duration: Stable for 24 months from manufacture date Handling: Minimise exposure to air and moisture Storage After Reconstitution: Temperature: 2–8°C (refrigerated) Container: Sterile, sealed vial or container Stability: Use within 7 days of reconstitution Preparation: Reconstitute with sterile water or 0.9% saline solution Freeze-Thaw: Avoid repeated freeze-thaw cycles Sterility: Maintain aseptic technique during and after reconstitution Discard: Any unused reconstituted solution after 7 days

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. SS31 Design and Mitochondrial Targeting Mechanism
   Szeto HH. (2006). Cell-permeable, mitochondria-targeted, peptide antioxidants. AAPS Journal, 8(2), E277–E283. https://doi.org/10.1007/BF02854898
   Foundational paper by the inventor of the SS peptide series, describing the design rationale for SS31 (Elamipretide) as a cell-permeable, mitochondria-targeted antioxidant tetrapeptide. Establishes the cardiolipin-binding mechanism and selective accumulation in the inner mitochondrial membrane.
2. SS31 and Cardiolipin Interaction: Preserving Mitochondrial Cristae
   Birk AV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261. https://doi.org/10.1681/ASN.2012121216
   Demonstrates that SS31 binds directly to cardiolipin on the inner mitochondrial membrane, stabilising cristae architecture, restoring electron transport chain efficiency, and improving ATP synthesis in ischaemic renal tissue — a key mechanistic study for mitochondrial bioenergetics research.
3. SS31 in Cardiac Ischaemia-Reperfusion Injury Models
   Cho J, et al. (2007). Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coronary Artery Disease, 18(3), 215–220. https://doi.org/10.1097/MCA.0b013e3280d609fe
   Demonstrates significant reduction in myocardial infarct size following SS31 administration in rat ischaemia-reperfusion models, establishing its cardioprotective profile and supporting research into mitochondrial ROS scavenging during oxidative injury.
4. SS31 and Skeletal Muscle Mitochondrial Function in Ageing
   Siegel MP, et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763–771. https://doi.org/10.1111/acel.12102
   Shows that acute SS31 treatment rapidly restores mitochondrial membrane potential, increases ATP production, and improves in vivo skeletal muscle contractile function in aged mice — providing key data for research into age-related mitochondrial decline and sarcopenia models.
5. Elamipretide (SS31) Clinical Translation: Heart Failure
   Gibson CM, et al. (2016). EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients with ST-segment elevation myocardial infarction. European Heart Journal, 37(16), 1296–1303. https://doi.org/10.1093/eurheartj/ehv597
   Phase 2a clinical trial evaluating the safety and tolerability of intravenous elamipretide (SS31/MTP-131) in STEMI patients, providing translational context for preclinical SS31 research and establishing the compound’s clinical pharmacokinetic and safety profile.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.